Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Jan 16, 2024 4:47pm
217 Views
Post# 35829982

RE:Multiple

RE:MultipleHi Camphikefish,  118M is that net revenue or is it gross revenue? Lets assume its net revenue of which I believe is the worst case scenario. 
To do a very rough estimate on potential share price take the 118,000,000 and divide probable shares after all warrants are exercised  300,000, 000 roughly = 39 cents a share earnings. Now we must apply PE (price earnings) ratio that this company fits into and that is Health growth a very high profile sector that has a range of 50 to 150 multiple. 

On the low end $0.39 × 50 = $19.50 
On the high side $0.39 × 150 = $58.50

Since your question was on a buyout my guess would have to be greatly over and above because of revenue from future cancer indications and also to include the vaccine/therapy treatments. 

<< Previous
Bullboard Posts
Next >>